Should I buy or sell Innoviva stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" INVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INVA, but not buy additional shares or sell existing shares. View INVA analyst ratings or view top-rated stocks .

What is Innoviva's stock price target for 2024?

3 Wall Street analysts have issued twelve-month price targets for Innoviva's shares. Their INVA share price targets range from $10.00 to $22.50. On average, they anticipate the company's share price to reach $15.17 in the next twelve months. This suggests a possible upside of 5.4% from the stock's current price. View analysts price targets for INVA or view top-rated stocks among Wall Street analysts .

How have INVA shares performed in 2023?

Innoviva's stock was trading at $13.25 at the start of the year. Since then, INVA shares have increased by 8.6% and is now trading at $14.39. View the best growth stocks for 2023 here .

Are investors shorting Innoviva?

Innoviva saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 9,610,000 shares, an increase of 7.1% from the October 31st total of 8,970,000 shares. Based on an average daily trading volume, of 668,000 shares, the short-interest ratio is presently 14.4 days. Approximately 15.2% of the company's stock are sold short. View Innoviva's Short Interest .

When is Innoviva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our INVA earnings forecast .

How were Innoviva's earnings last quarter?

Innoviva, Inc. (NASDAQ:INVA) released its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported $0.98 EPS for the quarter. The biotechnology company had revenue of $67.26 million for the quarter. Innoviva had a trailing twelve-month return on equity of 24.11% and a net margin of 17.17%.

What ETFs hold Innoviva's stock?

ETFs with the largest weight of Innoviva (NASDAQ:INVA) stock in their portfolio include LeaderShares Activist Leaders ETF (ACTV) , ETC 6 Meridian Small Cap Equity ETF (SIXS) , Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG) , Invesco S&P SmallCap Health Care ETF (PSCH) , SPDR S&P Pharmaceuticals ETF (XPH) , Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and iShares U.S. Pharmaceuticals ETF (IHE) . Harbor Health Care ETF (MEDI) .

What other stocks do shareholders of Innoviva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO) , Gilead Sciences (GILD) , Exelixis (EXEL) , Micron Technology (MU) , Advanced Micro Devices (AMD) , Pfizer (PFE) , Vertex Pharmaceuticals (VRTX) , NVIDIA (NVDA) , OPKO Health (OPK) and Sorrento Therapeutics (SRNE) .

Who are Innoviva's major shareholders?

Innoviva's stock is owned by many different retail and institutional investors. Top institutional investors include Westfield Capital Management Co. LP (3.19%), Charles Schwab Investment Management Inc. (1.23%), American Century Companies Inc. (1.20%), Bank of New York Mellon Corp (1.12%), Northern Trust Corp (1.13%) and Invesco Ltd. (1.03%). Insiders that own company stock include Alexander J Denner, George Bickerstaff , Innoviva, Inc, Marianne Zhen , Pavel Raifeld and Plc Glaxosmithkline. View institutional ownership trends .

How do I buy shares of Innoviva?

Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Innoviva Stock Price, News & Analysis (NASDAQ:INVA)

$14.39

+0.40 (+2.86%)

(As of 12/4/2023 ET)

Compare

Today's Range: $13.94
▼
$14.44
50-Day Range: $12.32
▼
$14.39
52-Week Range: $10.64
▼
$14.44

Volume: 670,241 shs
Average Volume: 657,444 shs
Market Capitalization: $922.21 million

P/E Ratio: 32.71
Dividend Yield: N/A
Price Target: $15.17

Innoviva MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 5.4% Upside
$15.17 Price Target
Short Interest: Bearish
15.16% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.33
Upright™ Environmental Score
News Sentiment: 0.64
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.34 out of 5 stars

Medical Sector

916th out of 952 stocks

Pharmaceutical Preparations Industry

421st out of 434 stocks

1.0

Analyst's Opinion

Consensus Rating
Innoviva has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $15.17, Innoviva has a forecasted upside of 5.4% from its current price of $14.39.
Amount of Analyst Coverage
Innoviva has received no research coverage in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
15.16% of the float of Innoviva has been sold short.
Short Interest Ratio / Days to Cover
Innoviva has a short interest ratio ("days to cover") of 14.4, which indicates bearish sentiment.
Change versus previous month
Short interest in Innoviva has recently increased by 7.13%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Innoviva does not currently pay a dividend.
Dividend Growth
Innoviva does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Innoviva has received a 60.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Private equity funds investing in the pharmaceuticals industry" product. See details.
Environmental Sustainability
The Environmental Impact score for Innoviva is -0.33.

2.0

News and Social Media Coverage

News Sentiment
Innoviva has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Innoviva this week, compared to 1 article on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Innoviva insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.40% of the stock of Innoviva is held by insiders.
Percentage Held by Institutions
99.12% of the stock of Innoviva is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Innoviva is 32.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.43.
Price to Earnings Ratio vs. Sector
The P/E ratio of Innoviva is 32.71, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 117.87.
Price to Book Value per Share Ratio
Innoviva has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Innoviva Stock (NASDAQ:INVA)

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

INVA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

INVA Stock News Headlines

December 4, 2023 | americanbankingnews.com

Innoviva, Inc. (NASDAQ:INVA) Sees Significant Growth in Short Interest

November 27, 2023 | msn.com

Innoviva (INVA) Price Target Increased by 7.14% to 15.30

December 5, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 18, 2023 | finance.yahoo.com

Insider Sell Alert: Marianne Zhen Offloads Shares of Innoviva Inc

November 14, 2023 | finance.yahoo.com

Innoviva, Inc. (NASDAQ:INVA) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

November 3, 2023 | finance.yahoo.com

Innoviva Inc (INVA) Reports Q3 2023 Financial Results: Net Income Drops to $82.0 Million

November 1, 2023 | finance.yahoo.com

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

November 1, 2023 | finance.yahoo.com

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

December 5, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

October 18, 2023 | finance.yahoo.com

Calculating The Intrinsic Value Of Innoviva, Inc. (NASDAQ:INVA)

October 9, 2023 | seekingalpha.com

Innoviva: A Lot Of Moving Parts

September 19, 2023 | finance.yahoo.com

Innoviva to Participate in the Cantor Global Healthcare Conference

September 18, 2023 | finance.yahoo.com

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

August 25, 2023 | finance.yahoo.com

Innoviva Appoints Stephen Basso as Chief Financial Officer

August 3, 2023 | finance.yahoo.com

Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

July 23, 2023 | fool.com

Innoviva (NASDAQ: INVA)

July 23, 2023 | finance.yahoo.com

Investors in Innoviva (NASDAQ:INVA) have unfortunately lost 11% over the last year

July 13, 2023 | benzinga.com

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Innoviva, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

July 11, 2023 | finance.yahoo.com

Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

June 21, 2023 | seekingalpha.com

Innoviva's Reward Isn't Worth The Risk

June 6, 2023 | finance.yahoo.com

Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference

May 23, 2023 | finance.yahoo.com

Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use

May 12, 2023 | msn.com

EF Hutton Reiterates Innoviva (INVA) Buy Recommendation

May 11, 2023 | finance.yahoo.com

Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases

May 11, 2023 | finance.yahoo.com

Is There An Opportunity With Innoviva, Inc.'s (NASDAQ:INVA) 35% Undervaluation?

May 9, 2023 | finance.yahoo.com

Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

April 28, 2023 | finance.yahoo.com

Innoviva Announces Retirement of Board Chairman

See More Headlines

Receive INVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/01/2023
Today: 12/04/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:INVA
Previous Symbol: NASDAQ:THRX
CUSIP: 88338T10
CIK: 1080014
Web: www.inva.com
Phone: (650) 238-9600
Fax: 650-827-8690
Employees: 101
Year Founded: 1996

Price Target and Rating

Average Stock Price Target: $15.17
High Stock Price Target: $22.50
Low Stock Price Target: $10.00
Potential Upside/Downside: +5.6%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.44
Trailing P/E Ratio: 32.64
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $213.92 million
Net Margins: 17.17%
Pretax Margin: 23.49%
Return on Equity: 24.11%
Return on Assets: 11.93%

Debt

Debt-to-Equity Ratio: 0.71
Current Ratio: 8.43
Quick Ratio: 7.31

Sales & Book Value

Annual Sales: $331.34 million
Price / Sales: 2.78
Cash Flow: $2.39 per share
Price / Cash Flow: 6.02
Book Value: $8.11 per share
Price / Book: 1.77

Miscellaneous

Outstanding Shares: 64,090,000
Free Float: 63,190,000
Market Cap: $920.33 million
Optionable: Optionable
Beta: 0.52

Social Links

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Pavel Raifeld C.F.A. (Age 39)
Chief Executive Officer
Comp: $754.67k
Ms. Marianne Zhen CPA (Age 54)
Chief Accounting Officer & Secretary
Comp: $530.21k
Mr. Stephen Basso M.B.A.
Chief Financial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Innoviva stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" INVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INVA, but not buy additional shares or sell existing shares.
View INVA analyst ratings or view top-rated stocks.
What is Innoviva's stock price target for 2024?: 3 Wall Street analysts have issued twelve-month price targets for Innoviva's shares. Their INVA share price targets range from $10.00 to $22.50. On average, they anticipate the company's share price to reach $15.17 in the next twelve months. This suggests a possible upside of 5.4% from the stock's current price.
View analysts price targets for INVA or view top-rated stocks among Wall Street analysts.
How have INVA shares performed in 2023?: Innoviva's stock was trading at $13.25 at the start of the year. Since then, INVA shares have increased by 8.6% and is now trading at $14.39.
View the best growth stocks for 2023 here.
Are investors shorting Innoviva?: Innoviva saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 9,610,000 shares, an increase of 7.1% from the October 31st total of 8,970,000 shares. Based on an average daily trading volume, of 668,000 shares, the short-interest ratio is presently 14.4 days. Approximately 15.2% of the company's stock are sold short.
View Innoviva's Short Interest.
When is Innoviva's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our INVA earnings forecast.
How were Innoviva's earnings last quarter?: Innoviva, Inc. (NASDAQ:INVA) released its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported $0.98 EPS for the quarter. The biotechnology company had revenue of $67.26 million for the quarter. Innoviva had a trailing twelve-month return on equity of 24.11% and a net margin of 17.17%.

What ETFs hold Innoviva's stock?: ETFs with the largest weight of Innoviva (NASDAQ:INVA) stock in their portfolio include LeaderShares Activist Leaders ETF (ACTV), ETC 6 Meridian Small Cap Equity ETF (SIXS), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and iShares U.S. Pharmaceuticals ETF (IHE).Harbor Health Care ETF (MEDI).
What other stocks do shareholders of Innoviva own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).
Who are Innoviva's major shareholders?: Innoviva's stock is owned by many different retail and institutional investors. Top institutional investors include Westfield Capital Management Co. LP (3.19%), Charles Schwab Investment Management Inc. (1.23%), American Century Companies Inc. (1.20%), Bank of New York Mellon Corp (1.12%), Northern Trust Corp (1.13%) and Invesco Ltd. (1.03%). Insiders that own company stock include Alexander J Denner, George Bickerstaff, Innoviva, Inc, Marianne Zhen, Pavel Raifeld and Plc Glaxosmithkline.
View institutional ownership trends.
How do I buy shares of Innoviva?: Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:INVA) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial